




STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergizes with T cell checkpoint blockade


Yaara Ofir-Rosenfeld¹, Lina Vasiliauskaite¹, Claire Saunders^{1,2}, Mark Albertella¹⁺, Marie Carkill³, Jezrom Self-Fordham³, Josefin-Beate Holz¹ and Oliver Rausch¹ ¹Storm Therapeutics Ltd, Cambridge, UK | ²Milner Therapeutics Institute, University of Cambridge, Cambridge, UK | ³Charles River, Portishead, UK *Current address: UCL Cancer Institute, London, UK | *Current address: Oncology R&D, AstraZeneca, Cambridge UK







Harnessing the Power of RNA Modification



In pre-clinical cancer models, STC-15 treatment inhibits tumour growth, activates innate immune pathways, and enhances the anti-tumour properties of anti-PD1 therapy, to generate a durable anti-tumour immune response. These data provide a rationale for the development of STC-15 as a novel treatment for solid tumour malignancies, as well as in combination with checkpoint inhibition. A Phase I, First-in-Human clinical trial starts in Q4 2022.

Summary

